公开(公告)号：US20170258777A1

公开(公告)日：2017-09-14

申请号：US15604904

申请日：2017-05-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dalton King ,  Lorin A. Thompson, III ,  Jianliang Shi ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Imadul Islam ,  John E. Macor

IPC: A61K31/454 ,  C07D401/04 ,  C07D403/04

CPC classification number: A61K31/454 ,  C07D401/04 ,  C07D403/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US20160081995A1

公开(公告)日：2016-03-24

申请号：US14882041

申请日：2015-10-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dalton King ,  Lorin A. Thompson, III ,  Jianliang Shi ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Imadul Islam ,  John E. Macor

IPC: A61K31/454

CPC classification number: A61K31/454 ,  C07D401/04 ,  C07D403/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US08722670B2

公开(公告)日：2014-05-13

申请号：US13627130

申请日：2012-09-26

Applicant: Bristol-Myers Squibb Company

Inventor： Dalton King ,  Richard E. Olson ,  John E. Macor ,  Imadul Islam ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier

IPC: C07D413/14 ,  C07D487/04 ,  A61K31/4709 ,  A61K31/4245

CPC classification number: C07D413/12 ,  C07D271/113 ,  C07D401/12 ,  C07D403/08 ,  C07D413/06 ,  C07D413/08 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

Abstract translation: 本公开内容通常涉及式I化合物，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是NR2B受体的配体，拮抗剂，可用于治疗中枢神经系统的各种疾病。

公开(公告)号：US20200071304A1

公开(公告)日：2020-03-05

申请号：US16502684

申请日：2019-07-03

Applicant: Bristol-Myers Squibb Company

Inventor： Imadul Islam ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Srinivas Cheruku ,  Poornima Shetty ,  Grandhi Venkat Ram Krishna Mohan Gupta ,  John E. Macor

IPC: C07D403/14 ,  C07D401/12 ,  C07D471/08 ,  A61P25/28 ,  A61P25/02 ,  A61P25/24 ,  A61P25/16 ,  C07D401/14 ,  C07D487/08

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US10344020B2

公开(公告)日：2019-07-09

申请号：US15767386

申请日：2016-10-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Imadul Islam ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Srinivas Cheruku ,  Poornima Shetty ,  Grandhi Venkat Ram Krishna Mohan Gupta ,  John E. Macor

IPC: C07D403/14 ,  C07D401/12 ,  C07D471/08 ,  A61P25/28 ,  A61P25/02 ,  A61P25/24 ,  A61P25/16 ,  C07D401/14 ,  C07D487/08

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US20190117638A1

公开(公告)日：2019-04-25

申请号：US16225850

申请日：2018-12-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dalton King ,  Lorin A. Thompson, III ,  Jianliang Shi ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Imadul Islam ,  John E. Macor

IPC: A61K31/454 ,  C07D403/04 ,  C07D401/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US20180000807A1

公开(公告)日：2018-01-04

申请号：US15706172

申请日：2017-09-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dalton King ,  Lorin A. Thompson, III ,  Jianliang Shi ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Imadul Islam ,  John E. Macor

IPC: A61K31/454 ,  C07D403/04 ,  C07D401/04

CPC classification number: A61K31/454 ,  C07D401/04 ,  C07D403/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US09221796B2

公开(公告)日：2015-12-29

申请号：US14589205

申请日：2015-01-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dalton King ,  Lorin A. Thompson, III ,  Jianliang Shi ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Imadul Islam ,  John E. Macor

IPC: C07D403/04 ,  C07D401/04

CPC classification number: A61K31/454 ,  C07D401/04 ,  C07D403/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

Abstract translation: 本公开内容通常涉及式I化合物，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是NR2B受体的配体，可用于治疗中枢神经系统的各种疾病。

公开(公告)号：US20150191452A1

公开(公告)日：2015-07-09

申请号：US14589205

申请日：2015-01-05

Applicant: Bristol-Myers Squibb Company

Inventor： Dalton King ,  Lorin A. Thompson, III ,  Jianliang Shi ,  Srinivasan Thangathirupathy ,  Jayakumar Sankara Warrier ,  Imadul Islam ,  John E. Macor

IPC: C07D403/04 ,  C07D401/04

CPC classification number: A61K31/454 ,  C07D401/04 ,  C07D403/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

Abstract translation: 本公开内容通常涉及式I化合物，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是NR2B受体的配体，可用于治疗中枢神经系统的各种疾病。